Last A$1.31 AUD
Change Today +0.01 / 0.77%
Volume 1.1M
ACR On Other Exchanges
Symbol
Exchange
OTC US
As of 1:10 AM 10/21/14 All times are local (Market data is delayed by at least 15 minutes).

acrux ltd (ACR) Snapshot

Open
A$1.30
Previous Close
A$1.30
Day High
A$1.34
Day Low
A$1.29
52 Week High
10/23/13 - A$3.03
52 Week Low
06/6/14 - A$0.75
Market Cap
217.3M
Average Volume 10 Days
977.4K
EPS TTM
A$0.17
Shares Outstanding
166.5M
EX-Date
09/4/14
P/E TM
7.7x
Dividend
A$0.11
Dividend Yield
17.95%
Current Stock Chart for ACRUX LTD (ACR)

Related News

No related news articles were found.

acrux ltd (ACR) Related Businessweek News

No Related Businessweek News Found

acrux ltd (ACR) Details

Acrux Limited is engaged in the development and commercialization of healthcare products in Australia, Switzerland, the United States, and internationally. Its marketed products comprise Axiron for the treatment of testosterone deficiency in men; Recuvyra for pain relief of dogs; and Evamist for menopausal symptoms. The company’s product under registration study includes Estradiol MDTS for menopausal symptoms. It is also developing products, which are in formulation stage for the treatment of non-melanoma skin cancer, anti-fungal, pain and inflammation, and other diseases, as well as developing product for the treatment of animal health. The company was founded in 1998 and is headquartered in West Melbourne, Australia.

Founded in 1998

acrux ltd (ACR) Top Compensated Officers

Executive Chairman
Total Annual Compensation: A$366.0K
Commercial Director
Total Annual Compensation: A$122.8K
Compensation as of Fiscal Year 2014.

acrux ltd (ACR) Key Developments

Acrux Limited Announces Management Changes

Acrux Limited announced that CFO and Company Secretary, Mr. Tony Di Pietro, has resigned. Ms. Sharon Papworth C.A. has been appointed to replace Mr. Di Pietro as the new CFO and Company Secretary effective September 29, 2014.

Acrux Limited to Report Fiscal Year 2014 Results on Aug 21, 2014

Acrux Limited announced that they will report fiscal year 2014 results at 9:45 AM, AUS Eastern Standard Time on Aug 21, 2014

Acrux Limited Declares Fully Franked Final Dividend Payable on September 22, 2014

Acrux declared a final dividend for 2013/14 financial year of 8 cents per share, fully franked. The record date for entitlement to the dividend is 8 September 2014 and the estimated date for dispatch of payment is 22 September 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACR:AU A$1.31 AUD +0.01

ACR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Austin Engineering Ltd A$1.09 AUD 0.00
Auxilium Pharmaceuticals Inc $31.05 USD +0.46
Bradken Ltd A$3.66 AUD -0.06
Emeco Holdings Ltd A$0.20 AUD +0.005
Seven Group Holdings Ltd A$6.42 AUD -0.27
View Industry Companies
 

Industry Analysis

ACR

Industry Average

Valuation ACR Industry Range
Price/Earnings 7.2x
Price/Sales 3.8x
Price/Book 4.8x
Price/Cash Flow 6.9x
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACRUX LTD, please visit www.acrux.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.